Cite
Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis.
MLA
Wang, Zexing, et al. “Risk of Hypertension with Regorafenib in Cancer Patients: A Systematic Review and Meta-Analysis.” European Journal of Clinical Pharmacology, vol. 70, no. 2, Feb. 2014, pp. 225–31. EBSCOhost, https://doi.org/10.1007/s00228-013-1598-1.
APA
Wang, Z., Xu, J., Nie, W., Huang, G., Tang, J., & Guan, X. (2014). Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 70(2), 225–231. https://doi.org/10.1007/s00228-013-1598-1
Chicago
Wang, Zexing, Jing Xu, Weiwei Nie, Guichun Huang, Jinhai Tang, and Xiaoxiang Guan. 2014. “Risk of Hypertension with Regorafenib in Cancer Patients: A Systematic Review and Meta-Analysis.” European Journal of Clinical Pharmacology 70 (2): 225–31. doi:10.1007/s00228-013-1598-1.